Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.

Kadrnozkova L, Vaneckova M, Sobisek L, Benova B, Kucerova K, Motyl J, Andelova M, Novotna K, Lizrova Preiningerova J, Krasensky J, Havrdova E, Horakova D, Uher T.

J Neurol Sci. 2018 May 15;388:87-93. doi: 10.1016/j.jns.2018.02.045. Epub 2018 Mar 6.

PMID:
29627038
2.

The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.

Uher T, Krasensky J, Sobisek L, Seidl Z, Bergsland N, Dwyer MG, Kubala Havrdova E, Zivadinov R, Horakova D, Vaneckova M.

J Neuroimaging. 2018 May;28(3):328-337. doi: 10.1111/jon.12505. Epub 2018 Feb 27.

PMID:
29485230
3.

Cognitive clinico-radiological paradox in early stages of multiple sclerosis.

Uher T, Krasensky J, Sobisek L, Blahova Dusankova J, Seidl Z, Kubala Havrdova E, Sormani MP, Horakova D, Kalincik T, Vaneckova M.

Ann Clin Transl Neurol. 2017 Dec 15;5(1):81-91. doi: 10.1002/acn3.512. eCollection 2018 Jan.

4.

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.

Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Nov 5;17:444-451. doi: 10.1016/j.nicl.2017.11.002. eCollection 2018.

5.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739. [Epub ahead of print]

PMID:
29143562
6.

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R.

J Neuroimaging. 2017 Nov;27(6):620-629. doi: 10.1111/jon.12445. Epub 2017 May 2.

PMID:
28464417
7.

Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Burgetova A, Dusek P, Vaneckova M, Horakova D, Langkammer C, Krasensky J, Sobisek L, Matras P, Masek M, Seidl Z.

AJNR Am J Neuroradiol. 2017 Jun;38(6):1079-1086. doi: 10.3174/ajnr.A5166. Epub 2017 Apr 27.

8.

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M.

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

9.

Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach.

Uher T, Vaneckova M, Sormani MP, Krasensky J, Sobisek L, Dusankova JB, Seidl Z, Havrdova E, Kalincik T, Benedict RH, Horakova D.

Eur J Neurol. 2017 Feb;24(2):292-301. doi: 10.1111/ene.13200. Epub 2016 Nov 22.

PMID:
27873386
10.

Reliable measurements of brain atrophy in individual patients with multiple sclerosis.

Smeets D, Ribbens A, Sima DM, Cambron M, Horakova D, Jain S, Maertens A, Van Vlierberghe E, Terzopoulos V, Van Binst AM, Vaneckova M, Krasensky J, Uher T, Seidl Z, De Keyser J, Nagels G, De Mey J, Havrdova E, Van Hecke W.

Brain Behav. 2016 Jul 19;6(9):e00518. eCollection 2016 Sep.

11.

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, Tyblova M, Ramasamy D, Zivadinov R, Horakova D.

Mult Scler. 2017 Feb;23(2):242-252. doi: 10.1177/1352458516650525. Epub 2016 Jul 11.

PMID:
27230790
12.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

Uher T, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Ramasamy D, Zivadinov R, Havrdova E, Kalincik T, Horakova D.

Mult Scler. 2017 Jan;23(1):51-61. doi: 10.1177/1352458516642314. Epub 2016 Jul 11.

PMID:
27053635
13.

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.

Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D.

Mult Scler. 2016 Nov;22(13):1709-1718. Epub 2016 Feb 16.

PMID:
26883943
14.

Hippocampal but not amygdalar volume loss in narcolepsy with cataplexy.

Nemcova V, Krasensky J, Kemlink D, Petrovicky P, Vaneckova M, Seidl Z, Rulseh A, Buskova J, Susta M, Sonka K.

Neuro Endocrinol Lett. 2015 Dec;36(7):682-8.

PMID:
26859591
15.

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R.

Mult Scler. 2016 May;22(6):770-81. doi: 10.1177/1352458515601903. Epub 2015 Sep 11.

PMID:
26362893
16.

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Fellows K, Uher T, Browne RW, Weinstock-Guttman B, Horakova D, Posova H, Vaneckova M, Seidl Z, Krasensky J, Tyblova M, Havrdova E, Zivadinov R, Ramanathan M.

J Lipid Res. 2015 Oct;56(10):2010-8. doi: 10.1194/jlr.M060970. Epub 2015 Aug 4.

17.

Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.

Varosanec M, Uher T, Horakova D, Hagemeier J, Bergsland N, Tyblova M, Seidl Z, Vaneckova M, Krasensky J, Dwyer MG, Havrdova E, Zivadinov R.

AJNR Am J Neuroradiol. 2015 Aug;36(8):1457-64. doi: 10.3174/ajnr.A4330. Epub 2015 Jun 25.

18.

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Eur J Neurol. 2015 Jul;22(7):1113-23. doi: 10.1111/ene.12716. Epub 2015 Apr 22.

PMID:
25904020
19.

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.

Uher T, Benedict RH, Horakova D, Bergsland N, Dusankova JB, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

J Neurol Sci. 2014 Dec 15;347(1-2):229-34. doi: 10.1016/j.jns.2014.10.002. Epub 2014 Oct 8.

PMID:
25456460
20.

MRI correlates of disability progression in patients with CIS over 48 months.

Uher T, Horakova D, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2014 Sep 28;6:312-9. doi: 10.1016/j.nicl.2014.09.015. eCollection 2014.

21.

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

Uher T, Blahova-Dusankova J, Horakova D, Bergsland N, Tyblova M, Benedict RH, Kalincik T, Ramasamy DP, Seidl Z, Hagermeier J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

J Neurol. 2014 Sep;261(9):1735-44. doi: 10.1007/s00415-014-7413-9. Epub 2014 Jun 22.

PMID:
24952618
22.

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.

Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Qu J, Havrdova E, Ramanathan M.

J Steroid Biochem Mol Biol. 2014 Sep;143:424-33. doi: 10.1016/j.jsbmb.2014.06.007. Epub 2014 Jun 17.

PMID:
24950029
23.

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study.

Zivadinov R, Chin J, Horakova D, Bergsland N, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Hagemeier J, Tyblova M, Carl E, Krasensky J, Vaneckova M, Seidl Z, Dwyer MG, Havrdova E, Ramanathan M.

J Neuroimmunol. 2014 Aug 15;273(1-2):58-64. doi: 10.1016/j.jneuroim.2014.04.012. Epub 2014 Apr 30.

PMID:
24907902
24.

The redox-sensitive chloroplast trehalose-6-phosphate phosphatase AtTPPD regulates salt stress tolerance.

Krasensky J, Broyart C, Rabanal FA, Jonak C.

Antioxid Redox Signal. 2014 Sep 20;21(9):1289-304. doi: 10.1089/ars.2013.5693. Epub 2014 Jun 26.

25.

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.

Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):859-64. doi: 10.1136/jnnp-2013-307106. Epub 2014 Jan 27.

PMID:
24470599
26.

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

Dolezal O, Gabelic T, Horakova D, Bergsland N, Dwyer MG, Seidl Z, Krasensky J, Ramasamy DP, Vaneckova M, Havrdova E, Zivadinov R.

Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S42-8. doi: 10.1016/j.clineuro.2013.09.020.

PMID:
24321154
27.

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes.

Weinstock-Guttman B, Horakova D, Zivadinov R, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M.

J Neuroimmunol. 2013 Oct 15;263(1-2):121-7. doi: 10.1016/j.jneuroim.2013.07.010. Epub 2013 Aug 2.

PMID:
23916695
28.

Thalamic atrophy is associated with development of clinically definite multiple sclerosis.

Zivadinov R, Havrdová E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Carl E, Kalincik T, Horáková D.

Radiology. 2013 Sep;268(3):831-41. doi: 10.1148/radiol.13122424. Epub 2013 Apr 23.

PMID:
23613615
29.

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91. doi: 10.1136/jnnp-2012-304740. Epub 2013 Apr 17.

PMID:
23595944
30.

Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years.

Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Potts JA, Kalincik T, Havrdová E, Horáková D.

AJNR Am J Neuroradiol. 2013 Oct;34(10):1931-9. doi: 10.3174/ajnr.A3503. Epub 2013 Apr 11.

31.

Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome.

Kalincik T, Guttmann CR, Krasensky J, Vaneckova M, Lelkova P, Tyblova M, Seidl Z, De Jager PL, Havrdova E, Horakova D.

Genes Immun. 2013 Jun;14(4):244-8. doi: 10.1038/gene.2013.17. Epub 2013 Apr 11.

PMID:
23575354
32.

Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study.

Zivadinov R, Tekwe C, Bergsland N, Dolezal O, Havrdova E, Krasensky J, Dwyer MG, Seidl Z, Ramasamy DP, Vaneckova M, Horakova D.

Mult Scler Int. 2013;2013:231345. doi: 10.1155/2013/231345. Epub 2013 Jan 10.

33.

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.

Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamaño-Blanco M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Zhang M, Yu H, Duan X, Kalincik T, Ramanathan M.

PLoS One. 2013;8(1):e53996. doi: 10.1371/journal.pone.0053996. Epub 2013 Jan 8.

34.

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.

Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, Havrdova E, Horakova D.

PLoS One. 2012;7(11):e50101. doi: 10.1371/journal.pone.0050101. Epub 2012 Nov 15.

35.

Stress-induced GSK3 regulates the redox stress response by phosphorylating glucose-6-phosphate dehydrogenase in Arabidopsis.

Dal Santo S, Stampfl H, Krasensky J, Kempa S, Gibon Y, Petutschnig E, Rozhon W, Heuck A, Clausen T, Jonak C.

Plant Cell. 2012 Aug;24(8):3380-92. Epub 2012 Aug 10.

36.

Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.

Vaneckova M, Kalincik T, Krasensky J, Horakova D, Havrdova E, Hrebikova T, Seidl Z.

Eur Neurol. 2012;68(1):23-7. doi: 10.1159/000337683. Epub 2012 Jun 6.

PMID:
22677920
37.

Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.

Bergsland N, Horakova D, Dwyer MG, Dolezal O, Seidl ZK, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

AJNR Am J Neuroradiol. 2012 Sep;33(8):1573-8. doi: 10.3174/ajnr.A3086. Epub 2012 Apr 12.

38.

Early predictors of non-response to interferon in multiple sclerosis.

Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E.

Acta Neurol Scand. 2012 Dec;126(6):390-7. doi: 10.1111/j.1600-0404.2012.01662.x. Epub 2012 Mar 16.

PMID:
22428845
39.

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.

Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E.

Clin Neurol Neurosurg. 2012 Sep;114(7):940-6. doi: 10.1016/j.clineuro.2012.02.014. Epub 2012 Mar 7.

PMID:
22402204
40.

Drought, salt, and temperature stress-induced metabolic rearrangements and regulatory networks.

Krasensky J, Jonak C.

J Exp Bot. 2012 Feb;63(4):1593-608. doi: 10.1093/jxb/err460. Epub 2012 Jan 30. Review.

41.

Volume of the amygdala is reduced in patients with narcolepsy - a structural MRI study.

Brabec J, Rulseh A, Horinek D, Pala A, Guerreiro H, Buskova J, Petrovicky P, Nemcova V, Krasensky J, Seidl Z, Nimsky C, Sonka K.

Neuro Endocrinol Lett. 2011;32(5):652-6.

PMID:
22167152
42.

[Total elbow replacement in patients with rheumatoid arthritis].

Güttler K, Landor I, Vavřík P, Popelka S, Sosna A, Krásenský J.

Acta Chir Orthop Traumatol Cech. 2011;78(5):423-30. Czech.

PMID:
22094156
43.

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event.

Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Ramanathan M.

J Neuroimmunol. 2011 Jul;236(1-2):76-80. doi: 10.1016/j.jneuroim.2011.04.011. Epub 2011 May 31.

PMID:
21621859
44.

Apolipoprotein E ε4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study.

Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaněčková M, Krásenský J, Zivadinov R.

Folia Biol (Praha). 2010;56(6):242-51.

45.

Multiple sclerosis and the accumulation of iron in the Basal Ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry.

Burgetova A, Seidl Z, Krasensky J, Horakova D, Vaneckova M.

Eur Neurol. 2010;63(3):136-43. doi: 10.1159/000279305. Epub 2010 Jan 30.

PMID:
20130410
46.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.

Mult Scler. 2009 Aug;15(8):965-76. doi: 10.1177/1352458509105229. Epub 2009 May 22.

PMID:
19465443
47.

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis.

Vaneckova M, Seidl Z, Krasensky J, Havrdova E, Horakova D, Dolezal O, Burgetova A, Masek M.

Eur Neurol. 2009;61(5):278-84. doi: 10.1159/000206852. Epub 2009 Mar 17.

PMID:
19295214
48.

A central role of abscisic acid in stress-regulated carbohydrate metabolism.

Kempa S, Krasensky J, Dal Santo S, Kopka J, Jonak C.

PLoS One. 2008;3(12):e3935. doi: 10.1371/journal.pone.0003935. Epub 2008 Dec 12.

49.

Microtubule-associated protein AtMPB2C plays a role in organization of cortical microtubules, stomata patterning, and tobamovirus infectivity.

Ruggenthaler P, Fichtenbauer D, Krasensky J, Jonak C, Waigmann E.

Plant Physiol. 2009 Mar;149(3):1354-65. doi: 10.1104/pp.108.130450. Epub 2008 Dec 12.

50.

Magnetic resonance volumetry of pathological brain foci in patients with systemic lupus erythematosus.

Podrazilová L, Peterová V, Olejárová M, Tegzová D, Krásenský J, Seidl Z, Kozelek P, Dostál C.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):604-10.

PMID:
18799091

Supplemental Content

Loading ...
Support Center